{"id":"NCT01484977","sponsor":"UCB Pharma","briefTitle":"eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam","officialTitle":"Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12","primaryCompletion":"2013-12","completion":"2013-12","firstPosted":"2011-12-05","resultsPosted":"2014-11-26","lastUpdate":"2018-07-18"},"enrollment":120,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Lacosamide","otherNames":["VIMPATÂ®","SPM927","Harkoseride"]}],"arms":[{"label":"Lacosamide","type":"EXPERIMENTAL"}],"summary":"The main purpose of this study is to evaluate the effectiveness of the study drug lacosamide (200-600 mg/day) when added to a stable dose of levetiracetam (1000-3000 mg/day) with withdrawal of the concomitant sodium channel blocking-antiepileptic drug (AEDs) in subjects not well controlled on their current regimen.","primaryOutcome":{"measure":"Retention at the End of the 21-week Treatment Period","timeFrame":"Duration of the Treatment Period (21 Weeks)","effectByArm":[{"arm":"Lacosamide","deltaMin":73.3,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":16},"locations":{"siteCount":54,"countries":["United States","Australia","Bulgaria","Denmark","France","Germany","Romania","Spain","Sweden"]},"refs":{"pmids":["27714769"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":120},"commonTop":["Dizziness","Headache","Fatigue","Nausea","Convulsion"]}}